Studying Drug Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived Cardiomyocytes
Extra-Cellular Field Potential and Electrical Impedance Analyses in High Throughput Systems
Recent withdrawals of prescription drugs from clinical use because of unexpected side effects on the heart have highlighted the need for more reliable cardiac safety pharmacology. Described is the use of cardiomyocytes derived from human embryonic stem cells (hESC) as a renewable, scalable and reproducible assay system on which to base cardiac safety screening.
Drug induced QT elongation has been observed as a side effect in certain clinically approved drugs, and is most commonly induced by affecting the rapid potassium current Ikr by binding to the hERG channel. Primary canine and rabbit Purkinje fibres and transgenic cell lines are the routinely employed preclinical in-vitro test systems that are currently available. Species differences and the lack of complex ion channel interactions in transgenic cell lines reduce the predictive value of these systems. Described is the use of Cytiva cardiomyocytes (CM) which are derived from human embryonic stem cells (hESC) and provide a relevant functional human model for use in preclinical safety assessment.
Take a look at the poster (pdf).
Ray Ismail, Bob Kendall, Dave Anderson, Gareth Phillips. GE Healthcare, Amersham Place, Little Chalfont, Buckinghamshire, England, UK HP7 9NA.